GMP-Compliant Manufacturing Scale-Up

This contract involves the scale-up of production for blood analogs or diagnostic materials in compliance with Good Manufacturing Practice (GMP) standards. The scope includes not only the manufacturing process but also the validation of these processes to ensure consistency and reliability. Additionally, there is a focus on implementing a robust quality control system to maintain the highest standards throughout production. Issued by the Defense Advanced Research Projects Agency under the Department of Defense, the subcontract solicits expertise in biopharmaceutical manufacturing aligned with NAICS code 325414, which covers biological product manufacturing. The contract was posted on May 27, 2026, with a response deadline of June 24, 2026. Although specific location details and points of contact are not provided, interested parties are expected to be capable of meeting stringent GMP requirements to support defense-related research and development initiatives.